Clinical Trial Update: Safety Study of Tasimelteon for Treatment of Non-24-Hour-Sleep-Wake Disorder in Blind Individuals With No Light Perception [Phase 3]

View source ↗

Summary

Phase 3 safety trial update for tasimelteon in blind individuals with no light perception and non-24-hour sleep-wake disorder; status indicates active but not r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-24-hour Sleep-wake Disorder

Drugs mentioned

• Tasimelteon (tasimelteon)

Snippet

Sponsor: Vanda Pharmaceuticals | Conditions: Non 24 Hour Sleep Wake Disorder | Phase 3 | Status: ACTIVE_NOT_RECRUITING